Global Hemophilia Treatment Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026

MarketResearch.biz delivers in-depth insights on the hemophilia treatment market in its upcoming report titled, “Global Hemophilia Treatment Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global hemophilia treatment market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the global hemophilia treatment market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report contains insightful and detailed information regarding the various key players operating in the global market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global hemophilia treatment market report has been segmented on the basis of type, product, distribution channel, and region.

Hemophilia is an inherited genetic bleeding disorder resulting in an individual lacking or having low levels of proteins called clotting factors. This impairs the body’s ability to control coagulation or blood clotting.  Hemophilia occurs more in males than females and is inherited as an X-linked recessive trait, in which the mother passes on a copy of the defective gene to a male child, and more rarely, both parents pass on copies of the defective gene to a female child. While males with hemophilia experience joint and muscle bleeding, females have unusually heavy reproductive bleeding, including menstrual periods or bleeding after childbirth.

Out of the three types of hemophilia, type A is more prevalent as compared to the other variants. Hemophilia A is a rare non-genetic form, in which autoantibodies develop against the plasma coagulation factor.

Rising prevalence of bleeding disorders, increasing awareness among populations, increasing Research & Development of novel clotting factors and technological advancements are key factors driving growth of the global hemophilia treatment market. However, lack of available medicines and high cost of treatment are restraining factors for market growth. However, advancements in gene therapy and approaching approval of drugs for treatment of hemophilia offer high potential growth opportunities in this market.

The hemophilia market in North America is estimated to remain dominant and contribute largest revenue share to the global hemophilia treatment market during the forecast period. Markets in Asia Pacific and Latin America are excepted to witness significant growth in the near future, owing to rising number of hemophilic patients, increasing awareness of these disorders, and technological advancements in these emerging economies. Moreover, owing to better diagnostic techniques, increasing prophylactic treatments, and growing medical research in Asia Pacific and Latin America, demand for recombinant and plasma-derived products are further increasing in these regions.

Market Segmentation:

Global hemophilia treatment market, by type

• Hemophilia A
• Hemophilia B
• Hemophilia C

Global hemophilia treatment market, by product:

• Plasma derived coagulation factor concentrates
• Recombinant coagulation factor concentrates
• Desmopressin
• Antifibrinolytic agents

Global hemophilia treatment drugs market, by distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• E-commerce

Global hemophilia treatment market, by region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

• Baxter International Inc.
• Grifols SA
• CSL Ltd.
• Octapharma AG
• Novo Nordisk
• Kedrion
• Pfizer Inc.
• Bayer AG
• Biogen Idec Inc.
• Hospira Inc.